key: cord-1043989-yovtj7je
authors: Pormohammad, Ali; Ghorbani, Saied; Khatami, Alireza; Razizadeh, Mohammad Hossein; Alborzi, Ehsan; Zarei, Mohammad; Idrovo, Juan‐Pablo; Turner, Raymond J.
title: Comparison of influenza type A and B with COVID‐19: A global systematic review and meta‐analysis on clinical, laboratory and radiographic findings
date: 2020-10-09
journal: Rev Med Virol
DOI: 10.1002/rmv.2179
sha: 24ac1fd46eeae64704b56ff699508602b3811215
doc_id: 1043989
cord_uid: yovtj7je

We compared clinical symptoms, laboratory findings, radiographic signs and outcomes of COVID‐19 and influenza to identify unique features. Depending on the heterogeneity test, we used either random or fixed‐effect models to analyse the appropriateness of the pooled results. Overall, 540 articles included in this study; 75,164 cases of COVID‐19 (157 studies), 113,818 influenza type A (251 studies) and 9266 influenza type B patients (47 studies) were included. Runny nose, dyspnoea, sore throat and rhinorrhoea were less frequent symptoms in COVID‐19 cases (14%, 15%, 11.5% and 9.5%, respectively) in comparison to influenza type A (70%, 45.5%, 49% and 44.5%, respectively) and type B (74%, 33%, 38% and 49%, respectively). Most of the patients with COVID‐19 had abnormal chest radiology (84%, p < 0.001) in comparison to influenza type A (57%, p < 0.001) and B (33%, p < 0.001). The incubation period in COVID‐19 (6.4 days estimated) was longer than influenza type A (3.4 days). Likewise, the duration of hospitalization in COVID‐19 patients (14 days) was longer than influenza type A (6.5 days) and influenza type B (6.7 days). Case fatality rate of hospitalized patients in COVID‐19 (6.5%, p < 0.001), influenza type A (6%, p < 0.001) and influenza type B was 3%(p < 0.001). The results showed that COVID‐19 and influenza had many differences in clinical manifestations and radiographic findings. Due to the lack of effective medication or vaccine for COVID‐19, timely detection of this viral infection and distinguishing from influenza are very important.

Influenza outbreaks are seen every year during the colder months of the year. Until now, four influenza pandemics have been reported, including the H1N1 (1918), the H2N2 (1957), the H3N2 (1967) and the H1N1 pandemic in 2009. 1 In addition, seasonal flu is reporting in different countries every year. Influenza mortality is associated with age, underlying disease and pregnancy. 2, 3 The most important clinical findings in patients with influenza are fever, cough and runny nose. 4, 5 According to the Centre for Disease different NA subtypes (H1-H18 and N1-N11, respectively). 6 Current subtypes of influenza A viruses that routinely circulate in people include flu A (H1N1) and A (H3N2) 6 . Type A subtypes often cause mild and symptomatic respiratory illness, but some subtypes such as H5N1 are highly pathogenic and have a higher mortality rate. 6 In the last 20 years, in addition to the influenza virus, other respiratory viruses belonging to coronavirus families such as severe acute respiratory syndrome (SARS) (in 2002) and Middle East respiratory syndrome (in 2012) were among the most severe respiratory pathogens. 6 In late 2019, the SARS-Cov-2 virus caused the COVID- 19 infection, and it became a pandemic disease in a short time. Between December 2019 and 26 April 2020, about three million people were infected with COVID-19, and about 300,000 died from the disease. Both influenza and SARS-Cov-2 viruses cause respiratory disease with a wide range of asymptomatic or mild to severe disease. 7 Also, both viruses are transmitted via contact, droplets and contaminated surfaces. 8 Moreover, basic reproduction number R zero (R0) for COVID-19 (1.5-5.7) is more significant than influenza (0.9-2.1), which shows that the SARS-Cov-2 virus can infect more people than influenza. [8] [9] [10] [11] [12] Children are the primary group of virus carriers in influenza infections. 13 Moreover, children, older adults, pregnant women, individuals with underlying chronic disease and immunosuppressed patients are at high risk of severe influenza infection. [13] [14] [15] While, in the COVID-19, children are less affected than adults and the older age with underlying conditions, and are associated with severe symptoms of the disease. 16 Among COVID-19 patients, the primary treatment is mostly supportive, although multiple experimental antiviral medications are being evaluated. 17, 18 Thus, prevention and rapid diagnosis of infected patients are crucial. Most of the clinical symptoms of COVID-19 patients are similar to influenza infections. Therefore, in this study, we attempted to distinguish the clinical symptoms, laboratory findings, radiographic signs and outcomes of confirmed COVID-19 and influenza patients.

All findings are compared to determine the unique features among each virus. These data could be helpful in the early diagnosis and prevention of infection as well as providing more reliable epidemiological data on a large scale for healthcare policies and future studies.

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA) guidelines. 19 

Duplicate studies were removed using EndNote X7 (Thomson Reuters). Records were initially reviewed by title and abstract by independent five authors (AP, SG, MR, AK and EA). The full text of potentially eligible records was retrieved and examined, and any disagreement was resolved by consensus. 

Studies without the number of confirmed cases, letters to editor, review articles, individual case reports and news reports were excluded. Duplicate data from the same patients were combined and counted as a single case when the data were reported more than one.

All COVID-19 included literature that was published in 2020, and all influenza studies were from 2000 to 2020. The following items were extracted from each article: first author, centre and study location, countries, sample collection time, patient follow-up time, the reference standard for infection confirmation, number of confirmed cases, study type, and all demographic, clinical, radiological, laboratory data and risk factor data. Four of our authors (Saied Ghorbani, Mohammad Hossein Razizadeh, Ehsan Alborzi and Alireza Khatami) independently extracted data, and all extracted data were checked randomly by another author (Ali Pormohammad); the differences were resolved by consensus.

Quality assessments of studies were performed by two reviewers independently according to the critical appraisal checklist recommended by the Joanna Briggs Institute, and disagreements were resolved by consensus. The checklist is composed of nine questions that reviewers addressed for each study. The 'Yes' answer to each question received one point. Thus, the final scores for each study could range from 0 to 9 (Table S2 ).

Data cleaning and preparation were done in Microsoft Excel 2010 (Microsoft©), and further analyses were carried out via Comprehensive Meta-Analysis Software Version 2.0 (Biostat). Determination of heterogeneity among the studies was undertaken using the chisquared test (Cochran's Q) to assess the appropriateness of pooling data. Depending on the heterogeneity test, we used either randomor fixed-effect model for pooled results. In the case of high heterogeneity (I 2 >50%), a random-effect model (M-H heterogeneity) was applied, while in low heterogeneity cases (I 2 < 50%), a fixed-effect model was used. 20 Percentages and means � SDs were calculated to describe the distributions of categorical and continuous variables, respectively. p-Values reflect study heterogeneity with <0.05 being significant. We also used the funnel plot, Begg's and Egger's tests based on the symmetry assumption to detect publication bias ( Figure S1 ).

The process of study selection is represented in Figure 1 . A total of 194,092 reports were screened for the analysis of patients with COVID-19 and influenza; 363,827 of them were excluded after the duplicate removing, title and abstract screening, and the full text of 611 reports were reviewed in full text. We excluded studies that did not report sufficient data. Out of 540 included studies, 157 studies met the inclusion criteria for COVID-19 and 383 for influenza. The characteristics of the selected articles are summarized in Table S5 . Of the 157 COVID-19 studies that were included in the analysis, 155 studies were in English and 2 of them were in Chinese languages. 21, 22 All COVID-19 studies were retrospective, published in 2020, and 150 studies were from China, 2 from the United States, 1 from Italy, 1 from Japan, 1 from the United Kingdom, 1 from Iran and 1 from Taiwan. All influenza studies were from 2000 to 2020, and out of 383 influenza studies, 251 studies were influenza A and 47 studies were influenza B.

Quality assessment of included studies was performed based on the critical appraisal checklist, and the final quality scores of the included studies are represented in Table S2 . In brief, studies by Chen, 23 Wang, 24 Huang, 25 Guan, 26 Zhang, 27 Cheng, 28 Li, 29 Wei Xu 30 and Song 31 had the highest quality of the COVID-19 studies available to date in the purpose of this study.

Overall, 75,164 confirmed patients with COVID-19 infection, 113,818 with influenza type A and 9266 with influenza type B were included in the meta-analysis, of which 51% (95% CI 50-52.2, p < 0.001) of COVID-19, 54% (95% CI 53-54.5, p < 0.001) of influenza type A and 52% (95% CI 48-55.5, p < 0.001) of influenza type B included patients who were male. Funnel plots for included studies did not detect significant publication bias ( Figure S1 ). patients, while it is presented in influenza type A by 47% (95% CI 43-52, p < 0.001) and influenza type B by 32% (95% CI 10-67, p < 0.001) of the patients (Figure 2 ).

Up to 26 April 2020, 51% (95% CI 44-58, p < 0.001) of COVID-19 patients had a history of recent travel or contact with endemic people, and 43.5% (95% CI 35-52, p < 0.001) had contacted with another person with respiratory symptoms. Another risk factor for COVID-19 was healthcare worker by 23% (95% CI 10-43, p < 0.001).

The most common comorbid chronic condition for COVID-19 and influenza type A is hypertension by 20% (95% CI 16-25, p < 0.001) and diabetes for influenza type B by 19% (95% CI 11-29, p < 0.001).

Acute respiratory syndrome (ARDS) occurred more frequently presented in influenza type A by 31.5% (95% CI 26-38, p < 0.001) compared to COVID-19 by 26.6% (95% CI 18-38, p < 0.001) and influenza type B by 0.8% (95% CI 0.1-6, p < 0.001). Virus co-infection occurred more frequently in influenza type B by 24% (95% CI 8-54, p < 0.001), in comparison to influenza type A by 8.5% (95% CI 5.5-13, p < 0.001) and COVID-19 by 4% (95% CI 1.5-10, p < 0.001) patients ( Figure 3) . Contact with another person with respiratory symptoms.

*Age is an exception, presented in mean age in years. **Greater than 50% is considered high heterogeneity, less than 50% is considered low heterogeneity. A low p-value (<0.05) is consistent with high heterogeneity.

PORMOHAMMAD ET AL. 

Based on the available data, the mean incubation period was 6 Case fatality rate of COVID-19 hospitalized patients was 6.5%

(95% CI 4.5-9, p < 0.001) ( Figure S2 ), influenza type A was 6% (95% 5-6.5, p < 0.001) and influenza type B was 3% (95% CI 2-4, p < 0.001).

The mortality rate in the influenza A subtypes are subtypes H1N1 (Figure 4) . (Table S4 ). Moreover, Spain had the highest mortality in influenza type B by 12.5% (95% CI 0.7-73, p < 0.9), and France had the lowest mortality rate by 0.9% (95% CI 0.6-1.5, p 0.9) ( Figure S3 ).

The laboratory findings showed that among 10,185 COVID-19 cases where data were available, lymphopenia was 62.5% (95% CI 45-72, p < 0.001), which is more than influenza type A (8820 cases) at 49%

(95% CI 35-56.4, p < 0.001) ( (0.8%). In addition, the most common comorbid chronic condition for which is similar to our result. Among influenza type A, the mortality rates in subtypes H5N1 (42%) and H7N9 (30%) were higher than subtypes H1N1 (5.5%), H3N2 (1.7%) and non-H1N1 (2%). The influenza mortality rate was associated with different age groups, in which a higher mortality rate is shown in people with ≥50-year-old ages (12%) in comparison to other age groups. These results indicated that older people are at risk of death from the flu. However, subtype H5N1 is fatal and life threatening for all age ranges.

Several limitations of this study exist. Publication bias and study heterogeneity are unavoidable in this type of study. Therefore, it should be considered when interpreting the outcomes of the reports and our final data-set. Furthermore, this study likely overestimates disease severity due to a lack of screening of asymptomatic or mildly symptomatic individuals and subsequent publication bias related to these factors. Likely, many infected persons have not been detected, thus falsely elevating the rates of hospitalization and mortality compared to the milder symptomatic population. Whether this issue is the same for all viruses evaluated here is unknown. The lower quality analysis and reporting in some of the included publications is another limitation of the study. To prevent language bias, we included reports in languages other than English.

Additionally, we searched for a variety of sites and databases to prevent Internet platform bias. Using Egger's regression test, we did not find significant publication bias. Journal bias is an issue facing those who carry out a meta-analysis, yet it does not usually affect the general conclusions. 33 However, we cannot reject the occurrence of other biases in this study, such as choice bias, since several journals are not indexed in Embase, Scopus, PubMed, Web of Science and the Cochrane library, and unpublished data from some regions of the world.

The results showed that despite the development of respiratory disease and similar transmission methods, COVID-19 and influenza had many differences in terms of involvement and severity of the pulmonary injury, mortality rate, laboratory finding and clinical symptoms. Due to the high transmissibility and the lack of effective medication or vaccine for COVID-19, timely detection of this viral infection and distinguishing from influenza are very important.

The role of viral, host, and secondary bacterial factors in influenza pathogenesis

Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies

Epidemiology of fatal cases associated with pandemic H1N1 influenza

Clinical analysis of 150 cases with the novel influenza A (H1N1) virus infection in Shanghai

Influenza B outbreak among influenza-vaccinated welfare home residents in Singapore

Other Viral Lung Infections

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Presumed asymptomatic carrier transmission of COVID-19

Pattern of early human-to-human transmission of Wuhan

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2

Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1)

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study

Severe 2009 H1N1 influenza in pregnant and postpartum women in California

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Virtual screening of an FDA Approved drugs database on two COVID-19 coronavirus proteins

Potential COVID-2019 3C-like Protease inhibitors designed using generative deep learning approaches

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Statistical aspects of the analysis of data from retrospective studies

Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province

Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 2019 novel coronavirus infection in China

Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan

Kidney impairment is associated with in-hospital death of COVID-19 patients

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Emerging coronavirus 2019-nCoV pneumonia

Respiratory Syncytial Virus--SARS, MERS and Other Viral Lung Infections

Empirical assessment of effect of publication bias on meta-analyses

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article

Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings

The authors have declared that no conflict of interests. 

The data that support the findings of this study are available from the corresponding author upon request.

https://orcid.org/0000-0002-7542-4794Saied Ghorbani https://orcid.org/0000-0001-9284-6983Mohammad Zarei https://orcid.org/0000-0002-2239-2055